title: Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs.
abstract: The pre-clinical immunogenicity of a combination vaccine containing 13-valent pneumococcal conjugate (13vPnC) vaccine (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F conjugated to CRM197) and nine-valent meningococcal B PorA vaccine (NonaMen; serosubtypes P1.7,16; P1.5-1,2-2; P1.19,15-1; P1.5-2,10; P1.12-1,13; P1.7-2,4; P1.22,14; P1.7-1,1 and P1.18-1,3,6), and any potential immunological interference between pneumococcal and MenB components of the vaccine were evaluated. NIH mice were immunized twice subcutaneously with the vaccines combined in one syringe, or given individually. Combining 13vPnC vaccine with NonaMen vaccine in one syringe had no negative effect on the induced antibody response against any MenB serosubtypes compared to separate injection of the vaccines, and the anti-pneumococcal antibody responses were enhanced. Furthermore, co-administration of the combination vaccine with a combined diphtheria/tetanus/acellular pertussis/inactivated poliomyelitis vaccine/Haemophilus influenzae type b-TT conjugate (DTaP/IPV-Hib) vaccine to New Zealand white rabbits at a different injection site did not affect the anti-pneumococcal polysaccharide and anti-PorA antibody titres. We conclude that no immunological interference was observed by combined administration of pneumococcal conjugate and meningococcal B vaccines in one syringe.
authors.affiliation: Department for Vaccine Research, Netherlands Vaccine Institute (NVI), P.O. Box 457, 3720 AL Bilthoven, The Netherlands. Germie.van.den.Dobbelsteen@NVI-vaccin.nl
authors.forename: Germie P J M
authors.initials: GP
authors.lastname: van den Dobbelsteen
authors.forename: Harry H
authors.initials: HH
authors.lastname: van Dijken
authors.forename: Subramonia
authors.initials: S
authors.lastname: Pillai
authors.forename: Loek
authors.initials: L
authors.lastname: van Alphen
mesh_terms: D000818:Animals; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D005260:Female; D018073:Haemophilus Vaccines; D008297:Male; D022401:Meningococcal Vaccines / Q000276:immunology* / Q000494:pharmacology; D051379:Mice; D022242:Pneumococcal Vaccines / Q000276:immunology* / Q000494:pharmacology; D011054:Poliovirus Vaccine, Inactivated; D018272:Porins / Q000276:immunology* / Q000378:metabolism; D011817:Rabbits; D013296:Streptococcus pneumoniae / Q000276:immunology; D017778:Vaccines, Combined / Q000276:immunology / Q000494:pharmacology; D018074:Vaccines, Conjugate / Q000276:immunology / Q000494:pharmacology
chemical_list: C513012:DTP-IPV-Hib vaccine; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D018073:Haemophilus Vaccines; D022401:Meningococcal Vaccines; D022242:Pneumococcal Vaccines; D011054:Poliovirus Vaccine, Inactivated; D018272:Porins; D017778:Vaccines, Combined; D018074:Vaccines, Conjugate; C057699:porin protein, Neisseria